Compare Quantum Computing Inc (QUBT) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quantum Computing Inc vs 10X Genomics Inc — how do they compare? Quantum Computing Inc trades at $7.92 (market cap $1.85B), while 10X Genomics Inc trades at $46.82 (market cap $5.48B). The key difference: 10X Genomics Inc is far larger — about 3× Quantum Computing Inc's market cap, and 10X Genomics Inc is trading nearer its 52-week high, Quantum Computing Inc nearer its low. Which is the better fit depends on your goals.
| QUBT | TXG | |
|---|---|---|
Market Cap | $1.85B | $5.48B |
Sector | Technology | Health |
52-Week High | $24.62 | $47.20 |
52-Week Low | $6.31 | $11.34 |
Enterprise Value | $871.49M | $5.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quantum Computing Inc. (QUBT) trades at $7.92, up 1.54% on the day, while technical indicators signal a bearish trend. The company reported minimal revenue of $682K in 2025 with a net loss of $18.67M, reflecting negative profit margins. Recent news highlights a shareholder investigation into potential fiduciary breaches, though some analysts remain optimistic about commercial growth prospects in quantum computing.
Despite a high analyst consensus price target of $26.00 and 75% buy ratings, QUBT faces significant financial risks including cash burn, negative earnings, and competitive pressures. The stock's outlook hinges on successful commercialization and revenue scaling, but current fundamentals suggest high volatility and speculative investment appeal.
TXG trades at $47.20, up 7.91% on the day, with a bullish technical signal from moving averages. The company reported Q1 2026 revenue that beat estimates, and net losses have narrowed significantly from -$255M in 2023 to -$44M in 2025. Operating cash flow turned strongly positive at $136M in 2025. Recent developments include the acquisition of Proteintech Genomics and a collaboration with Cleveland Clinic on bladder cancer diagnostics.
The outlook is mixed; improving fundamentals and strategic expansions support growth, but persistent net losses and a high EV/EBITDA of 133.91 pose valuation risks. Analyst consensus is divided with a $39.14 price target below the current price, indicating caution despite a majority buy/hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quantum Computing Inc
Quantum Computing Inc. is a company focused on providing accessible quantum computing and quantum-enhanced software solutions for complex problems. The company's technology is designed to run on both classical and quantum hardware, enabling businesses to explore the power of quantum computing today for applications in finance, drug discovery, and logistics. QUBT offers a platform that makes quantum algorithms and software available through the cloud, aiming to democratize access to this advanced computing paradigm.
Read more on QUBT →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
